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Resumo
A doença de Rendu-Osler-Weber, também conhecida por 
telangiectasia hemorrágica hereditária, é uma doença au-
tossómica dominante rara, frequentemente caracteriza-
da por epistáxis recorrente, telangiectasias mucocutâ-
neas e gastrointestinais e malformações arteriovenosas 
viscerais. Doentes com envolvimento gastrointestinal po-
dem apresentar um amplo espectro de gravidade, que 
pode variar de anemia ferropénica não complicada até 
hemorragia persistente e refractária. Os autores apresen-
tam o caso de uma mulher de 62 anos, admitida por ane-
mia na sequência de vários episódios de melenas, cuja 
avaliação endoscópica revelou múltiplas angiodisplasias 
no estômago e intestino delgado. Apesar de várias tenta-
tivas de terapêutica endoscópica e médica com agentes 
hormonais e octreotido, evoluiu para hemorragia persis-
tente e anemia grave, com necessidade de suporte trans-
fusional frequente. Imediatamente após ter iniciado be-
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Abstract
Rendu-Osler-Weber disease, also known as hereditary hem-
orrhagic telangiectasia, is a rare autosomal dominant disor-
der which is often characterized by recurrent epistaxis, mu-
cocutaneous and gastrointestinal telangiectasias, and viscer-
al arteriovenous malformations. Patients with gastrointestinal 
involvement can present with a wide spectrum of severity, 
which may vary from uncomplicated iron deficiency anemia 
to continuous and refractory bleeding. We present the case 
of a 62-year-old female, who was admitted with anemia fol-
lowing several episodes of melena, and whose endoscopic 
examination revealed multiple angiodysplasias in the stom-
ach and small bowel. Despite endoscopic and medical treat-
ment attempts with hormonal agents and octreotide, she de-
veloped persistent hemorrhage and severe anemia, requir-
ing frequent red blood cell transfusions. Immediately after 
initiating bevacizumab (7.5 mg/kg, every 3 weeks), complete 
cessation of bleeding episodes was observed. Currently, after 
1 year of follow-up, she maintained sustained remission with-
out the occurrence of adverse events.
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vacizumab (7,5 mg/kg, a cada 3 semanas) ocorreu cessa-
ção total dos episódios de hemorragia. Actualmente, 
após um ano de follow-up, mantém remissão sustentada 
sem a ocorrência de quaisquer eventos adversos.
© 2017 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Rendu-Osler-Weber disease (ROW; also known as he-
reditary hemorrhagic telangiectasia) is an autosomal 
dominant disorder which affects approximately 1 in 
5,000–8,000 individuals [1]. This entity is characterized 
by recurrent spontaneous epistaxis, multiple mucocuta-
neous and gastrointestinal telangiectasias, visceral arte-
riovenous malformations, and familial history, features 
that are included in the Curaçao diagnostic criteria [2, 3]. 
Gastrointestinal involvement usually arises after the 5th 
or 6th decade of life and its management may be particu-
larly challenging [4]. We present the case of a female pa-
tient, diagnosed with ROW 10 years earlier, who devel-
oped severe and persistent bleeding from gastrointestinal 
angiodysplasias. Despite having been submitted to endo-
scopic treatment with argon plasma coagulation (APC), 
hormonal therapy, and octreotide, she kept having con-
tinuous blood loss and significant transfusion require-
ments. Bevacizumab was started and followed by a dra-
matic and sustained clinical and biochemical response.
Clinical Case
A 62-year-old female was diagnosed with ROW at the age of 52 
due to recurrent epistaxis, multiple mucocutaneous telangiecta-
sias, and a positive family history. Ten years after the diagnosis, she 
presented to the emergency department with a recent history of 
fatigue, dizziness, and several episodes of melena. Laboratory stud-
ies revealed microcytic anemia (hemoglobin 4.5 g/dL, median cor-
puscular volume 69 fL), with low transferrin saturation (9%) and 
ferritin (4.1 ng/mL). She underwent an upper digestive endoscopy 
which described a few angiodysplasias in the gastric body and du-
odenum; APC was performed (Fig. 1). Since the number of gastro-
duodenal vascular lesions appeared to be insufficient to justify the 
degree of bleeding, a capsule endoscopy was performed, revealing 
multiple (more than 100) angiodysplasias in the duodenum, jeju-
num, and ileum (Fig.  2). Further investigation, which included 
colonoscopy, abdominal ultrasound, thoracic CT, and cranial MRI 
scans, detected no additional vascular abnormalities. Despite hav-
ing been submitted to coagulation of several vascular lesions 
through double-balloon enteroscopy and having initiated hor-
monal therapy with ethinylestradiol plus norethisterone (2 + 1 mg 
per day), hemorrhage and anemia persisted with the need for re-
peated transfusion of packed red blood cells (PRBC) (Fig.  3). 
Treatment with octreotide was started; however, a few hours after 
the first subcutaneous administration (100 μg), the patient pre-
sented with abdominal discomfort, nausea, and vomiting, leading 
to the discontinuation of the treatment. Given the maintenance of 
severe gastrointestinal bleeding, with PRBC transfusion depen-
dence (1 unit every other day to ensure levels of 6–7 g/dL of hemo-
globin), systemic therapy with bevacizumab was introduced at a 
dose of 7.5 mg/kg, intravenously, every 3 weeks. The patient’s clin-
ical response was immediate: since the beginning of the therapy, 
she had not required any transfusion support and only had one 
episode of melena when an infusion was postponed for 1 week due 
to an upper respiratory infection (Fig. 4). After 6 weeks of treat-
ment, the regimen was adjusted to 5 mg/kg every 3 weeks, without 
any change in clinical status. Currently, after 1 year of follow-up, 
she maintained complete clinical and biochemical remission with-
out any adverse event.
Discussion
Gastrointestinal involvement, the second most fre-
quent cause of bleeding in ROW patients, occurs in 
about one third of subjects with this condition [5]. Of 
those, approximately one half may develop significant 
disease and need regular blood transfusions [6]. The 
stomach and the duodenum are the most commonly af-
fected organs [7]; notwithstanding, small bowel angio-
dysplasias may be found in 56–89% of the cases [8, 9]. 
Although endoscopic treatment with APC may be useful 
for patients who do not achieve control with initial gen-
eral supportive measures, the use of multiple endoscop-
ic procedures in patients with continuous blood loss is 
not recommended [4]. For patients like ours, presenting 
with refractory bleeding and consequent severe anemia, 
several therapeutic possibilities were described to treat 
vascular lesions [10]. Hormonal therapy with an estro-
gen-progesterone combination proved to be beneficial 
in a small controlled study of 9 patients, 5 of which had 
ROW [11]. Nonetheless, the biggest randomized con-
trolled trial regarding this medical option failed to show 
a decrease in the number of bleeding episodes and trans-
fusion requirements in noncirrhotic subjects with gas-
trointestinal telangiectasias [12]. Although there are no 
comparative studies between them, both thalidomide 
and octreotide long-acting release were reported to be 
safe and effective for patients with gastrointestinal hem-
orrhage [13–16]; the latter has even reduced hospital ad-
missions and demonstrated a cost-effective benefit in 
this setting [15, 16]. In spite of being a generally safe 
drug, adverse events such as nausea, diarrhea, and flatu-
lence are relatively common within the first hours fol-
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lowing administration of octreotide [14]. Although these 
symptoms usually resolve after the first weeks, their oc-
currence may represent an additional challenge. In this 
case, as the patient developed gastrointestinal symptoms 
after the first administration of octreotide, she refused 
further treatment with this drug and we were not able to 
introduce the long-acting release formulation. There-
fore, given the behavior of her disease and her intoler-
ance to octreotide, we decided to initiate bevacizumab. 
This recombinant humanized monoclonal antibody is 
directed against the vascular endothelial growth factor, 
a protein which plays a critical role in the pathophysiol-
ogy of ROW [17]. In addition to having been success-
fully applied in the management of epistaxis and in the 
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Fig. 1. Upper digestive endoscopy revealing angiodysplasias in the gastric body (a) and second portion of the 
duodenum (b).
Fig. 2. Capsule endoscopy showing numerous andiodysplasias in the duodenum, jejunum, and ileum, some of which with active bleeding.
Fig. 3. Evolution of hemoglobin levels (g/dL) during hormonal 
therapy and despite weekly transfusion of packed red blood cells.
Bernardes/Santos/Loureiro/Borges/
Ramos
GE Port J Gastroenterol 2018;25:91–95
DOI: 10.1159/000481289
94
reduction of high cardiac output in patients with severe 
hepatic involvement [18], bevacizumab was shown to be 
effective controlling gastrointestinal bleeding in a few 
case reports [19–23]. In fact, patients who were refrac-
tory to several other medical and endoscopic approach-
es, and whose transfusion requirements ranged from 1 
unit of PRBC every week to about 300 units in a year, all 
were reported to have developed a significant decrease 
in bleeding episodes and transfusion needs [19–23]. Fur-
thermore, as in our case, authors described an extremely 
quick and long-term response, as well as the occurrence 
of early relapse following drug discontinuation [19–21]. 
Epperla et al. [21] published a case series comprising 5 
ROW patients (4 with epistaxis and only 1 with gastro-
intestinal hemorrhage) who have reduced their PRBC 
consumption by 51–100% and their total number of 
emergency department visits and hospitalizations by 
78%. Of note, hypertension and proteinuria were ob-
served in 2 and 1 of those patients, respectively, during 
the follow-up period [21]. The optimal dose and regi-
men for this agent are not fully established yet. Although 
the majority of authors used 5 or 7.5 mg/kg every 2 or 3 
weeks, successful use of low-dose bevacizumab (1 or 2 
mg/kg, every 3 weeks) was already reported, which could 
potentially decrease drug-related costs and adverse 
events [22, 23]. In our patient, in whom hormonal ther-
apy did not achieve clinical remission and who did not 
tolerate octreotide, intravenous bevazicumab at a dose 
of 5 mg/kg every 3 weeks was able to attain a dramatic 
and sustained response, without any complication. This 
case reinforces that this agent may be extremely useful 
for subjects who are either intolerant or refractory to al-
ternative treatment options.
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Fig. 4. Evolution of hemoglobin levels (g/
dL) before (solid line) and after (dashed 
line) the initiation of bevacizumab (BZV; 
first administration marked with an ar-
row). PRBC, packed red blood cells.
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